CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 2101-2111

  Krishnan, Vinu ^a,b   Xu, Xian ^a   Kelly, Dakota ^a   Snook, Adam ^c   Waldman, Scott A ^c   Mason, Robert W ^a,b   Jia, Xinqiao ^a   Rajasekaran, Ayyappan K ^a,d  

^a UNIVERSITY OF DELAWARE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Therapy Architects   (United States)

Author keywords

acute leukemia; CD19; doxorubicin; endocytosis; nanoparticles; xenograft model

Indexed keywords

ANTIBODY CONJUGATE; CD19 ANTIGEN; DOXORUBICIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B-CELL LEUKEMIA CELL LINE; BINDING COMPETITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PLASMA HALF LIFE; PRIORITY JOURNAL; SURFACE CHARGE; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICE, INBRED BALB C; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84930634417     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00071     Document Type: Article

References (34)

1. Facts 2012; The Leukemia & Lymphoma Society: 2013. http://www.lls.org/
2. Stuart, F. A.; Segal, T. Y.; Keady, S. Adverse psychological effects of corticosteroids in children and adolescents Arch. Dis. Child. 2005, 90, 500-506
3. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
4. Kamaly, N.; Xiao, Z.; Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation Chem. Soc. Rev. 2012, 41, 2971-3010
5. Krishnan, V.; Rajasekaran, A. K. Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy Clin. Pharmacol. Ther. 2014, 95, 168-178
6. FDA NEWS RELEASE: FDA approves Marqibo to treat rare type of leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315027.htm (published on August 9, 2012).
7. Uckun, F. M.; Jaszcz, W.; Ambrus, J. L.; Fauci, A. S.; Gajl-Peczalska, K.; Song, C. W.; Wick, M. R.; Myers, D. E.; Waddick, K.; Ledbetter, J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins Blood 1988, 71, 13-29
8. Cooper, L. J.; Al-Kadhimi, Z.; DiGiusto, D.; Kalos, M.; Colcher, D.; Raubitschek, A.; Forman, S. J.; Jensen, M. C. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies Blood Cells, Mol., Dis. 2004, 33, 83-89
9. Tedder, T. F. CD19: a promising B cell target for rheumatoid arthritis Nat. Rev. Rheumatol. 2009, 5, 572-577
10. Loken, M. R.; Shah, V. O.; Dattilio, K. L.; Civin, C. I. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development Blood 1987, 70, 1316-1324
11. Manzke, O.; Berthold, F.; Huebel, K.; Tesch, H.; Diehl, V.; Bohlen, H. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow Int. J. Cancer 1999, 80, 715-722
12. Szatrowski, T. P.; Dodge, R. K.; Reynolds, C.; Westbrook, C. A.; Frankel, S. R.; Sklar, J.; Stewart, C. C.; Hurd, D. D.; Kolitz, J. E.; Velez-Garcia, E.; Stone, R. M.; Bloomfield, C. D.; Schiffer, C. A.; Larson, R. A. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311 Cancer 2003, 97, 1471-1480
13. Mitchell, P.; Lee, F. T.; Hall, C.; Rigopoulos, A.; Smyth, F. E.; Hekman, A. M.; van Schijndel, G. M.; Powles, R.; Brechbiel, M. W.; Scott, A. M. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies J. Nucl. Med. 2003, 44, 1105-1112
14. Sapra, P.; Moase, E. H.; Ma, J.; Allen, T. M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments Clin. Cancer Res. 2004, 10, 1100-1111
15. Cheng, W. W.; Allen, T. M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv J. Controlled Release 2008, 126, 50-58
16. FDA NEWS RELEASE: FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm (published December 3, 2014).
17. Krishnan, V.; Xu, X.; Barwe, S. P.; Yang, X.; Czymmek, K.; Waldman, S. A.; Mason, R. W.; Jia, X.; Rajasekaran, A. K. Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhances Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine Mol. Pharm. 2013, 10, 2199-2210
18. Lipshultz, S. E.; Colan, S. D.; Gelber, R. D.; Perez-Atayde, A. R.; Sallan, S. E.; Sanders, S. P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N. Engl. J. Med. 1991, 324, 808-815
19. Lipshultz, S. E.; Lipsitz, S. R.; Sallan, S. E.; Dalton, V. M.; Mone, S. M.; Gelber, R. D.; Colan, S. D. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J. Clin. Oncol. 2005, 23, 2629-2636
20. Wang, X.; Gurski, L. A.; Zhong, S.; Xu, X.; Pochan, D. J.; Farach-Carson, M. C.; Jia, X. Amphiphilic Block Co-polyesters Bearing Pendant Cyclic Ketal Groups as Nanocarriers for Controlled Release of Camptothecin J. Biomater. Sci., Polym. Ed 2010, 22, 1275-1298
21. Altreuter, D. H.; Dordick, J. S.; Clark, D. S. Nonaqueous biocatalytic synthesis of new cytotoxic doxorubicin derivatives: Exploiting unexpected differences in the regioselectivity of salt-activated and solubilized subtilisin J. Am. Chem. Soc. 2002, 124, 1871-1876
22. Xu, X.; Sabanayagam, C. R.; Harrington, D. A.; Farach-Carson, M. C.; Jia, X. A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics Biomaterials 2014, 35, 3319-3330
23. Heuser, J. E.; Anderson, R. G. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation J. Cell Biol. 1989, 108, 389-400
24. Plummer, E. M.; Manchester, M. Endocytic uptake pathways utilized by CPMV nanoparticles Mol. Pharmaceutics 2013, 10, 26-32
25. Arnold, R. D.; Slack, J. E.; Straubinger, R. M. Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy J. Chromatography, B: Anal. Technol. Biomed. Life Sci. 2004, 808, 141-152
26. Benmerah, A.; Lamaze, C. Clathrin-coated pits: vive la difference? Traffic 2007, 8, 970-982
27. Christiansen, J.; Rajasekaran, A. K. Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther. 2004, 3, 1493-1501
28. Yoo, H. S.; Park, T. G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer J. Controlled Release 2001, 70, 63-70
29. Shuai, X.; Merdan, T.; Schaper, A. K.; Xi, F.; Kissel, T. Core-cross-linked polymeric micelles as paclitaxel carriers Bioconjugate Chem. 2004, 15, 441-448
30. Fahmy, T. M.; Samstein, R. M.; Harness, C. C.; Mark Saltzman, W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting Biomaterials 2005, 26, 5727-5736
31. Xiang, S.; Tong, H.; Shi, Q.; Fernandes, J. C.; Jin, T.; Dai, K.; Zhang, X. Uptake mechanisms of non-viral gene delivery J. Controlled Release 2012, 158, 371-378
32. Jiang, W.; Kim, B. Y.; Rutka, J. T.; Chan, W. C. Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 2008, 3, 145-150
33. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760
34. Petros, R. A.; DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discovery 2010, 9, 615-627